Ads
related to: fda approved gastric cancer treatment- Newly Approved Treatment
Learn More About This Newly
Approved Gastric Cancer Treatment.
- Contact A Representative
Connect With A Rep To Access Info
For This Newly Approved Treatment.
- Newly Approved Treatment
Search results
Results from the WOW.Com Content Network
Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, [3] and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.
[1] [10] It is the only available FDA-approved oral lipase inhibitor and is known on the market as Xenical and Alli. [5] Initially orlistat was developed as a treatment for dyslipidemia, not as an anti-obesity agent. When researchers found out that it promotes less energy uptake, the focus was switched to obesity. [11]
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...
(Reuters) - Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues ...
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...
In November 2017, the European Commission authorized Ontruzant, a biosimilar from Samsung Bioepis Co., Ltd, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. [15] [16] Ontruzant is the first trastuzumab biosimilar to receive regulatory approval in the European Union. [91]
The approval allows the use of the cancer drug, Rybrevant, in combination with J&J's existing drug, lazertinib, as a first-line treatment for non-small cell lung cancer (NSCLC) patients with a ...
The therapy, branded as Tevimbra, was approved as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma. The American Cancer Society estimates there ...
Ads
related to: fda approved gastric cancer treatment